Guardant Health Inc., a precision oncology company, has announced the results from the LIBERATE study, which have been published in ESMO Open. The study highlights the performance of Guardant Reveal, a blood test for detecting minimal residual disease $(MRD.AU)$ in patients with early-stage breast cancer. The results demonstrate the clinical validity and high performance of Guardant Reveal in predicting recurrence without the need for a tissue sample. The study retrospectively analyzed 290 blood samples from 95 patients, finding that Guardant Reveal demonstrated 100% sensitivity for distant recurrence in patients with ER+/HER2- breast cancer and 71% overall. Additionally, the test showed 100% specificity and a 100% positive predictive value for relapse. The findings indicate that post-operative detection of circulating tumor DNA (ctDNA) was significantly prognostic for event-free survival, with a median lead time of 152 days ahead of clinical recurrence. The full manuscript detailing these findings is available in ESMO Open.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.